Development of a Novel Diagnostic Biomarker Set for Rheumatoid Arthritis Using a Proteomics Approach

Abstract EN

Background.

Rheumatoid arthritis (RA) is an autoimmune disease that starts with inflammation of the synovial membrane.

Studies have been conducted to develop methods for efficient diagnosis of RA and to identify the mechanisms underlying RA development.

Blood samples can be useful for detecting disturbance of homeostasis in patients with RA.

Nanoliquid chromatography-tandem mass spectrometry (LC-MS/MS) is an efficient proteomics approach to analyze blood sample and quantify serum proteins.

Methods.

Serum samples of 18 healthy controls and 18 patients with RA were analyzed by LC-MS/MS.

Selected candidate biomarkers were validated by enzyme-linked immunosorbent assay (ELISA) using sera from 43 healthy controls and 44 patients with RA.

Results.

Thirty-eight proteins were significantly differentially expressed by more than 2-fold in healthy controls and patients with RA.

Based on a literature survey, we selected six candidate RA biomarkers.

ELISA was used to evaluate whether these proteins effectively allow distinguishing patients with RA from healthy controls and monitoring drug efficacy.

SAA4, gelsolin, and vitamin D-binding protein were validated as potential biomarkers of RA for screening and drug efficacy monitoring of RA.

Conclusions.

We identified a panel of three biomarkers for RA which has potential for application in RA diagnosis and drug efficacy monitoring.

Further, our findings will aid in understanding the pathogenesis of RA.